Welcome to the Mid-Atlantic Chapter!
Thank you for visiting the Mid-Atlantic Chapter of the FSHD Society which officially launched in 2018. We are here to build a local community of patients, family and friends, and help them connect and advocate for themselves and each other. Our hope for the future is to find a cure – Until then, we hope to bring a greater awareness to the community, and to help improve the quality of life of all those affected.
To contact us directly, please email:
Don’t forget to follow us on FACEBOOK
Would you like to get involved? Simply fill out the form in the sidebar.
Upcoming Events › Mid Atlantic Chapter Events
Meeting Agenda: - Bagels and Brainstorming - Please bring your ideas for future events! - Adapting Your Home for Accessibility - Karen Pitsley, AIA, Transforming Architecture LLC - Update on Fulcrum Therapeutics Clinical Trial - Doris G. Leung, MD, PhD, Frank Kolakowski, FSHD Society Board Member We hope to see you there! ~ Ann Kolakowski, Interim Chapter Director. Questions: Contact Ann: MidAtlanticChapter@FSHDSociety.org Please RSVP by November 14th:Find out more »
Jenny Hasenjaeger Levi Benson FSHD Society radio welcomes singer songwriters Levi Benson and Jenny Hasenjaeger this month. They share an FSHD diagnosis and a love of music. Levi Benson was featured earlier this year in FSHD Advocate and on our blog. Since the time he performed his first childhood song, “I Love My Lips,” made famous by VeggieTales’ Larry the Cucumber, Levi Benson’s lips have been crooning tunes. Those on the listening end of the Kansas musician's performances have been…Find out more »
This year, Acceleron’s ACE-083 drug is expected to complete its phase 2b trial, and Fulcrum is conducting its trial of Dr. Rabi Tawil the first drug intended to repress DUX4, the gene implicated in causing FSHD. This is a good time to brush up on the vocabulary of clinical trials and the FDA approval process, and learn how to navigate the path to volunteering for trials. Your guide is Rabi Tawil, MD, who is principal investigator for several clinical trials…Find out more »